Friday, 22 Jun 2018

You are here

Consensus on OP Drug Holidays

The association of very rare events, like osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF), with bisphosphonate use has changed the long-term management of anti-resorptive therapy.

Bisphosphonates and denosumab have proven efficacy in fracture reduction, but the optimal use and duration remains unclear.  A recent systematic review of the literature has resulted in the following expert opinion consensus: 

  • Extending bisphosphonate treatment beyond 3–5 years does not confer additional benefit in low-risk populations.
  • Treatment re-initiation (usually 1–3 years after bisphosphonate withdrawal) depends on risk factors, new fractures and bone mineral density.
  • The evidence regarding denosumab discontinuation is limited but caution is advised, as there may be a “rebound effect” with regard to fractures.

Discontinuation of bisphosphonates may be considered in all patients who have been on bisphosphonates (alendronate, risedronate or zoledronic acid) for more than five years, But the same cannot be said for ibandronate and denosumab, as the evidence is limited.

If the patient has not experienced fractures before or during therapy and the fracture risk is low, a “drug holiday” can be considered.  

There is no solid evidence for the duration of the drug holiday, but, 1–2 years for risedronate, 3–5 years for alendronate and 3–6 years for zoledronic acid are suggested. After this time, the patient should be reassessed.

Aanti-osteoporotic treatment should be resumed when there is a new fracture or if the fracture risk has increased or BMD remains low (femoral neck T-score ≤−2.5),

In the case of denosumab discontinuation, close monitoring is suggested, due to the possibility of rebound fractures.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Update on Osteoporosis

This session was an update on the management of osteoporosis given by Professor Christian Roux from France.

He emphasised the use of composite risk score like the FRAX. He highlighted that the risk of vertebral fracture is increased by both the recency and severity of previous vertebral fracture. So it is important that those with vertebral fractures are followed up and treated appropriately to prevent subsequent fractures.

Restless Sleep and Inactivity Intertwined in OA

Adults with osteoarthritis (OA) of the knee who frequently experienced restless sleep were less likely to engage in potentially beneficial moderate-to-vigorous physical activity, analysis of data from the Osteoarthritis Initiative found.

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Bisphosphonate Drug Holidays May Result in Fractures

A report in Endocrine Practice shows that drug holidays from bisphosphonates results in a 15% risk of fractures.  (Citation source: http://bit.ly/2FHbFwp)

USPSTF Recommendations on Vitamin D, Calcium Supplementation to Prevent Fractures

The U.S. Preventive Services Task Force (USPSTF) concludes current scientific evidence is insufficient regarding the use of vitamin D and calcium, alone or in combination, to prevent fractures in men and premenopausal women. The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D and 1,000 mg or less of calcium to prevent fractures in postmenopausal women. Current scientific evidence is insufficient regarding the use of vitamin D and calcium at doses greater than 400 IU of vitamin D and greater than 1,000 mg of calcium in postmenopausal women.